Search

Search Constraints

You searched for: Author/Creator Jemec, G.B.E.

Search Results

11. Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials. (14th August 2019)

12. Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials. (1st November 2019)

13. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. (30th January 2020)

16. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. (11th November 2014)

17. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. (1st December 2014)